EUVIMED · CrossrefZeitschrift
Lung Cancer
ISSN 0169-5002 · Elsevier BV
Neueste Artikel
Efficacy and safety of primary granulocyte colony-stimulating factor prophylaxis in patients with small-cell lung cancer receiving first-line platinum–etoposide plus a programmed death-ligand 1 inhibitor: A multicenter retrospective observational study (G-GUARD; TORG-TG2504)
Association of the IASLC histologic grading system with aggressive pathologic features in invasive non-mucinous lung adenocarcinoma
First Korean experience with shape-sensing robotic-assisted bronchoscopy integrated with mobile cone-beam CT: Results from the prospective ULSAN-ION study
Adverse events in placebo arms of phase III lung cancer trials: a systematic review and meta-analysis
Radiologic phenotype and the size dependence of adverse histologic features and recurrence in resected lung adenocarcinoma
Environmental asbestos exposure and lung cancer burden: Considerations of the dose–response
Coexistence of Osimertinib-Resistant and Osimertinib-Sensitive cell states in an EGFR-Mutant NSCLC model derived at osimertinib resistance
Lung cancer detection beyond screening eligibility through an incidental lung nodule program
Heterogeneous response and progression patterns during tarlatamab therapy in relapsed small cell lung cancer
Risk-adapted multimodality care for elderly limited-stage small-cell lung cancer
Exponential growth and slow-growing tumours in screen-detected lung cancers: findings from the NELCIN-B3 LDCT screening study in China
Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study
Longitudinal transcriptomic profiling of paired early and metastatic EGFR-mutant lung adenocarcinomas reveals molecular programs associated with disease progression
Systemic and intracranial activity of antibody–drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis
Rethinking the clock: Is treatment-free interval truly predictive of platinum sensitivity in small-cell lung cancer?
Characteristics and outcomes of patients with advanced or metastatic non–small cell lung cancer harboring a HER2-activating mutation: a real-world retrospective cohort study using a US clinico-genomic database
A Wide pCR Divide: Neoadjuvant immunotherapy versus targeted therapy in resectable NSCLC
Treatment-cycle–resolved peripheral blood T-cell GP73 dynamics are associated with clinical benefit during PD-1/PD-L1 inhibitor-based therapy in NSCLC
Bridging the molecular and immune landscapes of pleural mesothelioma: Implications for immune checkpoint inhibitor response
Patient factors affecting unplanned admission or emergency department attendance following systemic anti-cancer therapy for advanced non-small cell lung cancer: A population-based retrospective cohort study
Two decades of progress in lung cancer outcomes in Australia: Population-based trends by histological subtype and stage at diagnosis
Distinct spatial immune microenvironment features of different EGFR mutation subtypes in early-stage lung adenocarcinoma
Environmental asbestos exposure and lung cancer burden compared with mesothelioma in rural Türkiye: A 33-Year population-based cohort study
Changes in HER2 protein expression before and after EGFR TKI therapy in EGFR-mutant non-small cell lung cancer: a real world paired-biopsy study
Interstitial lung disease in patients treated with antibody–drug conjugates: a review
Clinicopathological and prognostic validation of pulmonary carcinoid/NET G3: evidence for a distinct subgroup of well-differentiated neuroendocrine neoplasms
Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer
Refining N1 classification: prognostic validation of N1 subdivision in resected non-small cell lung cancer
Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study
Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Jahrgänge
2026 · 6132025 · 6552024 · 4692023 · 4612022 · 4232021 · 5462020 · 6062019 · 5932018 · 5662017 · 4682016 · 4592015 · 4782014 · 5142013 · 6592012 · 6132011 · 5472010 · 4242009 · 6102008 · 3592007 · 4502006 · 5072005 · 1.8052004 · 3572003 · 1.5272002 · 3012001 · 2962000 · 1.0641999 · 2381998 · 2781997 · 1.3171996 · 8281995 · 1.2111994 · 1.5951993 · 5491992 · 2701991 · 1.1451990 · 3311989 · 4661988 · 511987 · 387
EUVIMED